Inotek Pharmaceuticals Corp (NASDAQ:ITEK) shares are on a rapid 70% descent after the firm announced top-line results this morning from the Phase 3 …
Piper Jaffray analyst Joshua Schimmer was out pounding the table on Inotek Pharmaceuticals Corp (NASDAQ:ITEK) Tuesday, reiterating an Overweight rating and raising the price target from $9 to $29, …
Inotek Pharmaceuticals Corp (NASDAQ:ITEK) shares are up 10.67% to $17.